Glioblastoma multiforme tanılı olgularda radyoterapi sonrasında tümör rekürrensi ve radyonekroz ayırımında perfüzyon MRG ve MR spektroskopinin rolü
The role of perfusion MRİ and MR spectroscopy in differentiation of tumor recurrence and radionecrosis of the patients diagnosis with glioblastoma multiforme after radyoterapi
- Tez No: 324085
- Danışmanlar: PROF. DR. MEHMET CEM ÇALLI
- Tez Türü: Tıpta Uzmanlık
- Konular: Radyoloji ve Nükleer Tıp, Radiology and Nuclear Medicine
- Anahtar Kelimeler: glioblastoma multiforme, perfusion weighted imaging, MR spectroscopy, radionecrosis, recurrence, glioblastoma multiforme, perfusion weighted imaging, MR spectroscopy, radionecrosis, recurrence
- Yıl: 2012
- Dil: Türkçe
- Üniversite: Ege Üniversitesi
- Enstitü: Tıp Fakültesi
- Ana Bilim Dalı: Radyoloji Ana Bilim Dalı
- Bilim Dalı: Belirtilmemiş.
- Sayfa Sayısı: 68
Özet
Purpose: GBM is the most frequent primary malignant brain tumor in adults. Optimal treatment modality is postoperative radiotherapy alone or in combination with concomitant adjuvant chemotherapy after as widest as possible surgical resection. The difficulty in evaluation after RT is distinguishing residual or recurrent tumor from radionecrosis. Radionecrosis is very similar to the clinical features and natural history of recurrent tumor. Therefore, differentiation of these two entites is very important and is often difficult. Contrast-enhanced MRI is the preferred method in these patients after follow-up radiotherapy. However, this method is insufficient. The aim of this study was to determine the additional value of perfusion MRI and MR spectroscopy to contrast enhanced MRI in the differentiation of tumor recurrence and radionecrosis after radiotherapy in patients with GBM.Materials and Methods: Contrast enhanced MR, perfusion MR and MR spectroscopy imaging findings of 40 patients (24 male, 16 female) who were diagnosed as GBM and treated with surgery and radiotherapy were examined rectospectively between January 2009 and July 2012. Radionecrosis group, 14 (35%), recurrence group, 26 (65%) patients were assessed. All patients were investigated at 1.5 and 3 Tesla MR system including conventional MR, diffusion-weighted, perfusion-weighted MRI and MR spectroscopy imaging. rCBV, rCBF values of perfusion MR examination and Cho, Cr, NAA values, Cho / Cr, Cho / NAA ratios of MR spectroscopy examination were evaluated.Results: 6 of 14 cases of radionecrosis (43%) were histopatologically diagnosed. Mean time of diagnosis of radionecrosis and recurrent tumor group was 9.00 ± 6:53 months and 8.04 ± 3.93 months, respectively. Mean rCBV value was calculated 3.79 ± 2.41 in radionecrosis group and 5.46 ± 2.19 in recurrence group . Mean rCBF value was 3.21 ± 1.99 in radionecrosis group and 5.17 ± 2.41 in recurrent group. In radionecrosis group, rCBV and rCBF values were statistically significantly lower than those of recurrence group. (p = 0.032, p = 0.013). Cho / Cr ratios were 2.55 ± 1.63 in radionecrosis group and 2.52 ± 1.60 in recurrence group; Cho / NAA ratios were 4.15 ± 3.69 in radionecrosis group and 3.24 ± 2.55 in recurrent group is measured. Results of MR spectroscopy were not statistically significant different between two analysed groups.Conclusion: As a result, in our opinion, for differentiation of tumor recurrence and radionecrosis after radiotherapy in patients with GBM, perfusion MR and MR spectroscopy imaging should be performed in addition to conventional MR imaging on follow-up examinations.
Özet (Çeviri)
Purpose: GBM is the most frequent primary malignant brain tumor in adults. Optimal treatment modality is postoperative radiotherapy alone or in combination with concomitant adjuvant chemotherapy after as widest as possible surgical resection. The difficulty in evaluation after RT is distinguishing residual or recurrent tumor from radionecrosis. Radionecrosis is very similar to the clinical features and natural history of recurrent tumor. Therefore, differentiation of these two entites is very important and is often difficult. Contrast-enhanced MRI is the preferred method in these patients after follow-up radiotherapy. However, this method is insufficient. The aim of this study was to determine the additional value of perfusion MRI and MR spectroscopy to contrast enhanced MRI in the differentiation of tumor recurrence and radionecrosis after radiotherapy in patients with GBM.Materials and Methods: Contrast enhanced MR, perfusion MR and MR spectroscopy imaging findings of 40 patients (24 male, 16 female) who were diagnosed as GBM and treated with surgery and radiotherapy were examined rectospectively between January 2009 and July 2012. Radionecrosis group, 14 (35%), recurrence group, 26 (65%) patients were assessed. All patients were investigated at 1.5 and 3 Tesla MR system including conventional MR, diffusion-weighted, perfusion-weighted MRI and MR spectroscopy imaging. rCBV, rCBF values of perfusion MR examination and Cho, Cr, NAA values, Cho / Cr, Cho / NAA ratios of MR spectroscopy examination were evaluated.Results: 6 of 14 cases of radionecrosis (43%) were histopatologically diagnosed. Mean time of diagnosis of radionecrosis and recurrent tumor group was 9.00 ± 6:53 months and 8.04 ± 3.93 months, respectively. Mean rCBV value was calculated 3.79 ± 2.41 in radionecrosis group and 5.46 ± 2.19 in recurrence group . Mean rCBF value was 3.21 ± 1.99 in radionecrosis group and 5.17 ± 2.41 in recurrent group. In radionecrosis group, rCBV and rCBF values were statistically significantly lower than those of recurrence group. (p = 0.032, p = 0.013). Cho / Cr ratios were 2.55 ± 1.63 in radionecrosis group and 2.52 ± 1.60 in recurrence group; Cho / NAA ratios were 4.15 ± 3.69 in radionecrosis group and 3.24 ± 2.55 in recurrent group is measured. Results of MR spectroscopy were not statistically significant different between two analysed groups.onclusion: As a result, in our opinion, for differentiation of tumor recurrence and radionecrosis after radiotherapy in patients with GBM, perfusion MR and MR spectroscopy imaging should be performed in addition to conventional MR imaging on follow-up examinations.
Benzer Tezler
- Radyoterapi ile eş zamanlı ve adjuvan temozolomid tedavisi uygulanmış glioblastoma multiformeli olgularda progresyon ve psödoprogresyon ayrımının perfüzyon MRG ile değerlendirilmesi
Evaluation of differentiaton between progression and pseudoprogression in glioblastome multiforme cases taking radiotherapy with concomitant and adjuvant temozolomid treatment via perfusion MRG
OLGUN ŞAHİN
Tıpta Uzmanlık
Türkçe
2010
Radyoloji ve Nükleer TıpEge ÜniversitesiRadyoloji Ana Bilim Dalı
PROF. DR. M. CEM ÇALLI
- Afyonkarahisar Sağlık Bilimleri Üniversitesi Tıp Fakültesi beyin ve sinir cerrahisi kliniğinde opere edilen astrositom olgularının değerlendirilmesi: Retrospektif çalışma
Evaluation of meningiom cases operated at neurosurgery clinic of Afyonkarahisar HEALTH Sciences University Faculty of Medicine: A retrospective study
AKIN CENGİZ
Tıpta Uzmanlık
Türkçe
2022
NöroşirürjiAfyonkarahisar Sağlık Bilimleri ÜniversitesiBeyin ve Sinir Cerrahisi Ana Bilim Dalı
PROF. DR. ADEM ASLAN
- Glioblastoma multiforme'de konvansiyonel ve hipofraksiyone radyoterapi rejimlerinin karşılaştırılması ve prognostik faktörler
Başlık çevirisi yok
MEHMET ARSLAN
Tıpta Uzmanlık
Türkçe
2000
Radyoloji ve Nükleer Tıpİstanbul ÜniversitesiRadyasyon Onkolojisi Ana Bilim Dalı
PROF.DR. A. N. KARADENİZ
- Glioblastoma multiformede konkomitant ve adjuvan temozolomid ile enoxaparin kullanımının radyoterapiye katkısı
In glioblastoma multiforme, concomitant and adjuvantemazolamid with enoxaparin for contribution of radiation therapy
FATİME AĞGİL
Tıpta Uzmanlık
Türkçe
2009
OnkolojiDicle ÜniversitesiRadyasyon Onkolojisi Ana Bilim Dalı
YRD. DOÇ. DR. S. BURHANEDTİN ZİNCİRCİOĞLU
- Glioblastoma multiformeli olgularda total rezeksiyon sonrası uygulanan kemoterapinin etkileri
Başlık çevirisi yok
ENİS KURUOĞLU
Tıpta Uzmanlık
Türkçe
2006
NöroşirürjiOndokuz Mayıs ÜniversitesiNöroşirürji Ana Bilim Dalı
PROF.DR. FAHRETTİN ÇELİK